Aurintricarboxylic Acid

Aurintricarboxylic Acid

SCHEMBL4644958

N.N.N.N.O=C(O)C1=CC(=C(c2ccc(O)c(C(=O)O)c2)c2ccc(O)c(C(=O)O)c2)C=CC1=O

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.97
KMT2A Q03164 4/20 0.97
C9 P02748 3/20 0.97
CYP2C9 P11712 3/20 0.97
CYP2C19 P33261 3/20 0.97
HIF1A Q16665 3/20 0.97
CYP1A2 P05177 2/20 0.97
CYP2D6 P10635 2/20 0.97
APEX1 P27695 2/20 0.97
CTH P32929 2/20 0.97
KDM4E B2RXH2 2/20 0.97
ALDH1A1 P00352 2/20 0.97
HSPD1 P10809 2/20 0.97
THRB P10828 2/20 0.97
HPGD P15428 2/20 0.97
ALOX15 P16050 2/20 0.97
BRCA1 P38398 2/20 0.97
RECQL P46063 2/20 0.97
HSPE1 P61604 2/20 0.97
HSD17B10 Q99714 2/20 0.97

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aurintricarboxylic Acid SCHEMBL30831678 1.00 MEN1 (0.97) MEN1KMT2AC9CYP2C9CYP2C19
Aurintricarboxylic Acid SCHEMBL29395768 1.00 MEN1 (0.97) MEN1KMT2AC9CYP2C9CYP2C19
Aurintricarboxylic Acid SCHEMBL10791075 1.00 MEN1 (0.97) MEN1KMT2AC9CYP2C9CYP2C19
Aurintricarboxylic Acid SCHEMBL515038 1.00 MEN1 (0.97) MEN1KMT2AC9CYP2C9CYP2C19
Aurintricarboxylic Acid SCHEMBL29450069 0.99 MEN1 (1.00) MEN1KMT2AC9CYP2C9CYP2C19
Aurintricarboxylic Acid SCHEMBL98495 0.99 MEN1 (1.00) MEN1KMT2AC9CYP2C9CYP2C19
Aurintricarboxylic Acid SCHEMBL29353681 0.99 MEN1 (1.00) MEN1KMT2AC9CYP2C9CYP2C19
Aurintricarboxylic Acid SCHEMBL6158321 0.97 MEN1 (0.97) MEN1KMT2AC9CYP2C9CYP2C19
Aurintricarboxylic Acid SCHEMBL15874321 0.97 MEN1 (0.97) MEN1KMT2AC9CYP2C9CYP2C19
Aurintricarboxylic Acid SCHEMBL6847597 0.96 MEN1 (0.95) MEN1KMT2AC9CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101400436-A Method and apparatus for forming chromonic nanoparticles 3M INNOVATIVE PROPERTIES CO (US) 2009-04-01 CN disclosed
EP-1957190-A2 METHOD AND APPARATUS FOR FORMING CHROMONIC NANOPARTICLES 3M Innovative Properties Company (US) 2008-08-20 EP disclosed
WO-2008054412-A2 METHOD AND APPARATUS FOR FORMING CHROMONIC NANOPARTICLES 3M INNOVATIVE PROPERTIES COMPANY (US) 2008-05-08 WO disclosed
US-20080063714-A1 Compositions for Encapsulation and Controlled Release 3M INNOVATIVE PROPERTIES COMPANY 2008-03-13 US disclosed
US-20070128291-A1 Method and Apparatus for Forming Chromonic Nanoparticles 3M INNOVATIVE PROPERTIES COMPANY 2007-06-07 US disclosed
EP-1651035-A2 COMPOSITIONS FOR ENCAPSULATION AND CONTROLLED RELEASE 3M Innovative Properties Company (US) 2006-05-03 EP disclosed
WO-2005012488-A2 COMPOSITIONS FOR ENCAPSULATION AND CONTROLLED RELEASE 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070128291-A1 Method and Apparatus for Forming Chromonic Nanoparticles CHMP4B, ANXA6, ATXN10 MEN1 813/4885KMT2A 4590/4885C9 665/4885
US-20080063714-A1 Compositions for Encapsulation and Controlled Release CHMP4B, DDC, ANXA5 MEN1 1943/4885KMT2A 3203/4885C9 1350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.